# Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup

> **NCT00579345** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 1522 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Cell culture derived seasonal trivalent influenza vaccine (cTIV)
- **BIOLOGICAL:** Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
- **BIOLOGICAL:** cTIV or eTIV_a
- **BIOLOGICAL:** cTIV+PV OR eTIV_a+PV

## Key facts

- **NCT ID:** NCT00579345
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 1522 (ACTUAL)
- **Last updated:** 2017-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00579345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00579345, "Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00579345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*